Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice (Q42218132)

18 October 2017

Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice (English)

1 reference

18 October 2017

0 references

1 reference

Yingxia Wen

1

1 reference

18 October 2017

James Monroe

2

1 reference

18 October 2017

Christine Linton

3

1 reference

18 October 2017

Jacob Archer

4

1 reference

18 October 2017

Clayton W Beard

5

1 reference

18 October 2017

Susan W Barnett

6

1 reference

18 October 2017

Giuseppe Palladino

7

1 reference

18 October 2017

Peter W Mason

8

1 reference

18 October 2017

Andrea Carfi

9

1 reference

18 October 2017

Anders E Lilja

10

1 reference

18 October 2017

language of work or name

English

0 references

publication date

14 May 2014

1 reference

18 October 2017

1 reference

18 October 2017

32

1 reference

18 October 2017

30

1 reference

18 October 2017

3796-3804

1 reference

Antiviral strategies to combat cytomegalovirus infections in transplant recipients

18 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Epitope-specific distribution of IgG subclasses against antigenic domains on glycoproteins of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Entry of herpesviruses into mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Role of human cytomegalovirus UL131A in cell type-specific virus entry and release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Two novel spliced genes in human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Vaccine prevention of maternal cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2014.05.004

1 reference

18 October 2017

1 reference